Safety & Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM

See also
Status	Clinical Trial	Phase
Completed	`NCT02223637` - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Completed	`NCT01452438` - Safety Surveillance of MenACWY-CRM Vaccine in Children	N/A
Completed	`NCT01434680` - Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers	Phase 2
Completed	`NCT01452464` - Safety of MenACWY-CRM Vaccination in Adolescents	N/A
Completed	`NCT02173704` - Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.	Phase 3
Completed	`NCT01682876` - Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.	Phase 3
Recruiting	`NCT04023929` - Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays
Completed	`NCT01453348` - Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine	Phase 3
Completed	`NCT01214837` - Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life	Phase 3
Completed	`NCT03378258` - Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Recruiting	`NCT04239430` - Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study
Completed	`NCT01973218` - Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.	Phase 3
Completed	`NCT01717638` - Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1	Phase 3
Completed	`NCT01725217` - Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia	Phase 3
Completed	`NCT01466387` - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Phase 3
Completed	`NCT01000311` - A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months	Phase 3
Completed	`NCT02140762` - Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents	Phase 2
Completed	`NCT02141516` - Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects	Phase 3
Completed	`NCT01478347` - A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults	Phase 3
Completed	`NCT01823536` - Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose	Phase 4

NCT number	NCT01994629
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	November 2013
Completion date	October 2014

Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms